Mouse Anti-CNG Channel Monoclonal Antibody, Unconjugated, Clone CNC 9C1 from ABR-Affinity BioReagents
Anti-IRF7 Polyclonal Antibody, Unconjugated from Invitrogen
Rabbit Anti-Rat Synapsin I, phospho (Ser603) Monoclonal Antibody, Clone PS603 from Invitrogen
Mouse Anti-MMP-20 Monoclonal Antibody, Unconjugated, Clone MMP2/2C1 from ABR-Affinity BioReagents
Biology Products:(Date:11/19/2009)...wswire-FirstCall/ -- Omeros Corporation (Nasdaq: ... for the third quarter ended September 30, 2009. F...os reported a net loss of $3.9 million, or $1.34 p...n, or $2.54 per share, for the same period in 2008...e Company reported a net loss of $15.5 million, or...
(Date:11/19/2009)...ALTHAM, Mass., Nov. 19 Arlington M... that the leading driver of antibiotic selection i... activity against gram-positive and gram-negative ...n cause nosocomial pneumonia, surveyed European ph...s that provide appropriate coverage against common...
(Date:11/19/2009)... is honored by latest award for revolutionary hear...WEB) November 16, 2009 -- Popular Science Magazine...ng aid from InSound Medical a winner of its covete...egory. Chosen from thousand... the hearing canal for up to four months while pro...
(Date:11/18/2009)...lka-dotted postage stamp that can sniff out poison...rs. , As reported in the Sept. 13 issue of the j... team at the University of Illinois have developed...oxic industrial chemicals (TICs) that is simple, f...s. This sensor array could be useful in detecting...
Breaking Biology Technology:Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3Popular Science Awards Lyric “Invisible” Hearing Aid 2009 “Best of What's New” Award 2Popular Science Awards Lyric “Invisible” Hearing Aid 2009 “Best of What's New” Award 3Opto-electronic nose sniffs out toxic gases 2Opto-electronic nose sniffs out toxic gases 3